Starting April 21, you’ll be asked to log in or sign up for a free account after viewing 10 content pages each month.
Don’t worry—creating an account is quick and easy, and it comes with added benefits! Once logged in, you’ll not only continue accessing the content you already enjoy, but you’ll also unlock exclusive features like interactive donut plots for variant protein effects and variant impacts across the gene.
Stay tuned for these updates, and thank you for being part of our community!
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Tislelizumab |
Synonyms | |
Therapy Description |
Tevimbra (tislelizumab) is a human monoclonal antibody that targets PD-1 (PDCD1), thereby blocking the binding of PD-L1 (CD274) and potentially resulting in activation of a T-cell immune response against tumor cells (PMID: 32769013, PMID: 32561638, PMID: 32540858). Tevimbra (tislelizumab) is FDA-approved for use in patients with unresectable or metastatic esophageal squamous cell carcinoma (FDA.gov). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Tislelizumab | Tevimbra | BGB-A317|tislelizumab-jsgr | Immune Checkpoint Inhibitor 149 PD-L1/PD-1 antibody 124 | Tevimbra (tislelizumab) is a human monoclonal antibody that targets PD-1 (PDCD1), thereby blocking the binding of PD-L1 (CD274) and potentially resulting in activation of a T-cell immune response against tumor cells (PMID: 32769013, PMID: 32561638, PMID: 32540858). Tevimbra (tislelizumab) is FDA-approved for use in patients with unresectable or metastatic esophageal squamous cell carcinoma (FDA.gov). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04802876 | Phase II | Tislelizumab Spartalizumab | Efficacy of Tislelizumab and Spartalizumab Across Multiple Cancer-types in Patients With PD1-high mRNA Expressing Tumors (ACROPOLI) | Active, not recruiting | ESP | 0 |
NCT02407990 | Phase I | Tislelizumab | Study of the Safety, Pharmacokinetics and Antitumor Activities of BGB-A317 in Subjects With Advanced Tumors | Completed | USA | NZL | AUS | 2 |
NCT05245760 | Phase II | Tislelizumab | ChemoRadiation And Tislelizumab for Esophageal/EGJ Cancer (CRATER) | Withdrawn | USA | 0 |
NCT05366829 | Phase II | Tislelizumab | Tislelizumab Consolidation After Liver-Directed Therapy for Hepatocellular Carcinoma | Recruiting | USA | 0 |
NCT06529523 | Phase II | Tislelizumab | Tislelizumab in People With Colorectal Cancer | Recruiting | USA | 1 |
NCT03430843 | Phase III | Docetaxel Paclitaxel Tislelizumab Irinotecan | A Study of BGB-A317 Versus Chemotherapy as Second Line Treatment in Patients With Advanced Esophageal Squamous Cell Carcinoma | Completed | USA | ITA | GBR | FRA | ESP | DEU | BEL | 4 |
NCT05909904 | Phase II | LBL-007 + Tislelizumab Tislelizumab BGB-A425 + Tislelizumab BGB-A425 + LBL-007 + Tislelizumab | Tislelizumab in Combination With Investigational Agents in Participants With Head and Neck Squamous Cell Carcinoma | Active, not recruiting | USA | TUR | ITA | GBR | FRA | ESP | CAN | AUS | 6 |
NCT04164199 | Phase III | Pamiparib + Tislelizumab Pemetrexed Disodium + Tislelizumab Tislelizumab Capecitabine + Tislelizumab Pamiparib | Study of Tislelizumab and/or Pamiparib Containing Treatments in Participants With Advanced Malignancies | Enrolling by invitation | USA | TUR | POL | NZL | ITA | FRA | AUS | 6 |
NCT04732494 | Phase II | BGBA1217 + Tislelizumab Tislelizumab | AdvanTIG-203: Anti-PD-1 Monoclonal Antibody Tislelizumab (BGB-A317) Combined With or Without Anti-TIGIT Monoclonal Antibody Ociperlimab (BGB-A1217) in Participants With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma | Completed | FRA | ESP | 4 |
NCT05635708 | Phase II | Nab-paclitaxel Cisplatin BGB-A445 + Tislelizumab Paclitaxel Tislelizumab Carboplatin Pemetrexed Disodium LBL-007 + Tislelizumab | A Study of Tislelizumab in Combination With Investigational Agents in Participants With Non-Small Cell Lung Cancer | Active, not recruiting | USA | ROU | ITA | FRA | ESP | CAN | BRA | AUS | 7 |
NCT04952597 | Phase II | Tislelizumab BGBA1217 + Tislelizumab | Study of Ociperlimab Plus Tislelizumab Plus Chemoradiotherapy in Participants With Untreated Limited-Stage Small Cell Lung Cancer | Completed | USA | 2 |
NCT05502250 | Phase II | Cisplatin + Gemcitabine + Tislelizumab Tislelizumab | Tislelizumab, Gemcitabine and Cisplatin for R/R Hodgkin Lymphoma Followed by Tislelizumab Consolidation in Patients in Metabolic Complete Remission (HOVON164HL) | Recruiting | NLD | DNK | BEL | 0 |
NCT04813107 | Phase Ib/II | APL-1202 + Tislelizumab Tislelizumab | A Study to Evaluate the Safety and Efficacy of Oral APL-1202 in Combination With Tislelizumab Compared to Tislelizumab Alone as Neoadjuvant Therapy in Patients With Muscle Invasive Bladder Cancer (ANTICIPATE) | Unknown status | USA | 1 |
NCT03745222 | Phase III | Tislelizumab Cisplatin + Etoposide + Tislelizumab Carboplatin + Paclitaxel + Tislelizumab Cisplatin + Etoposide Carboplatin + Paclitaxel | A Study of Tislelizumab (BGB-A317) Plus Chemoradiotherapy Followed by Tislelizumab Monotherapy in Newly Diagnosed, Stage III Subjects With Locally Advanced, Unresectable Non-small Cell Lung Cancer (RATIONALE001) | Terminated | USA | ROU | POL | NZL | NLD | ITA | IRL | HUN | GRC | GBR | FRA | FIN | ESP | DEU | CAN | BEL | 7 |
NCT05622071 | Phase II | Tislelizumab | Testing Immunotherapy for Patients With Liver Cancer and Moderately Altered Liver Functions (HESTIA) | Recruiting | FRA | 0 |
NCT03412773 | Phase III | Tislelizumab Sorafenib | Phase 3 Study of BGB-A317 Versus Sorafenib in Patients With Unresectable HCC | Completed | USA | POL | ITA | GBR | FRA | ESP | DEU | CZE | 3 |
NCT06919705 | Phase II | Zanubrutinib Tislelizumab Tislelizumab + Zanubrutinib | Testing Zanubrutinib and Tislelizumab as Well as Standard of Care for the Treatment of Patients With Progressive Lymphoma Post Anti-CD19 CAR-T Cell Therapy (OZUHN-024) | Not yet recruiting | 0 | |
NCT04746924 | Phase III | Tislelizumab BGBA1217 + Tislelizumab Pembrolizumab | A Study of Ociperlimab With Tislelizumab Compared to Pembrolizumab in Participants With Untreated Lung Cancer | Active, not recruiting | USA | TUR | POL | NLD | ITA | FRA | ESP | DEU | BRA | AUS | ARG | 8 |
NCT04866017 | Phase III | Durvalumab BGBA1217 + Tislelizumab Tislelizumab | A Study to Compare Ociperlimab Plus Tislelizumab Versus Durvalumab Following Concurrent Chemoradiotherapy (cCRT) in Patients With Stage III Unresectable Non-Small Cell Lung Cancer | Terminated | USA | ESP | AUS | 2 |
NCT03419897 | Phase II | Tislelizumab | Study of BGB-A317 in Patients With Previously Treated Unresectable HCC | Completed | POL | ITA | GBR | FRA | ESP | DEU | 2 |
NCT05977673 | Phase II | Tislelizumab | Efficacy and Safety of Frontline Tislelizumab in Patients With de Novo Hodgkin Lymphoma Unsuitable for Standard Frontline Chemotherapy: a Phase II, Open-label Study (FIL_Tisle-HL) | Recruiting | ITA | 0 |
NCT06332274 | Phase III | Tislelizumab | tislelizUMaB in canceR Patients With molEcuLar residuaL Disease (UMBRELLA) | Not yet recruiting | FRA | 0 |
NCT04318080 | Phase II | Tislelizumab | Tislelizumab in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma | Completed | USA | AUS | 0 |
NCT03783442 | Phase III | Cisplatin Paclitaxel Tislelizumab Oxaliplatin Fluorouracil Capecitabine | A Study of Tislelizumab (BGB-A317) in Combination With Chemotherapy as First Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma | Completed | USA | ROU | POL | ITA | GBR | FRA | ESP | DEU | CZE | BEL | AUS | 5 |
NCT05014815 | Phase II | BGBA1217 + Tislelizumab Tislelizumab | Ociperlimab With Tislelizumab and Chemotherapy in Participants With Untreated Metastatic Non-Small Cell Lung Cancer | Completed | USA | GRC | FRA | ESP | AUT | AUS | 2 |
NCT04837859 | Phase II | Tislelizumab Dacarbazine + Doxorubicin + Tislelizumab + Vinblastine | Phase II Trial of Individualized Immunotherapy in Early-Stage Unfavorable Classical Hodgkin Lymphoma (INDIE) | Recruiting | DEU | 0 |